agile therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. our lead product candidate, twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as ag200-15, is a once-weekly prescription contraceptive patch that recently completed phase 3 trials. twirla is based on our proprietary transdermal patch technology, called skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. for more information, please visit the company website at www.agiletherapeutics.com. connect with us on twitter at @agilether.
Company profile
Ticker
AGRX
Exchange
Website
CEO
Alfred Altomari
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
AGRX stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
9 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Agile Therapeutics Announces Delisting from Nasdaq
25 Mar 24
8-K
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
14 Mar 24
424B5
Prospectus supplement for primary offering
23 Feb 24
424B5
Prospectus supplement for primary offering
23 Feb 24
8-K
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
23 Feb 24
8-K
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
15 Feb 24
S-1/A
IPO registration (amended)
7 Feb 24
Transcripts
AGRX
Earnings call transcript
2023 Q4
28 Mar 24
AGRX
Earnings call transcript
2023 Q3
9 Nov 23
AGRX
Earnings call transcript
2023 Q2
9 Aug 23
AGRX
Earnings call transcript
2023 Q1
11 May 23
AGRX
Earnings call transcript
2022 Q4
22 Mar 23
AGRX
Earnings call transcript
2022 Q3
8 Nov 22
AGRX
Earnings call transcript
2022 Q2
11 Aug 22
AGRX
Earnings call transcript
2022 Q1
13 May 22
AGRX
Earnings call transcript
2021 Q4
30 Mar 22
AGRX
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Scott M Coiante
4 Oct 23
3
Scott M Coiante
25 Aug 23
4
Amy Welsh
30 Jun 23
4
Paul Korner
30 Jun 23
4
ALFRED ALTOMARI
30 Jun 23
4
Robert G Conway
30 Jun 23
4
Geoffrey Gilmore
30 Jun 23
4
Josephine Torrente
9 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.87 mm | 2.87 mm | 2.87 mm | 2.87 mm | 2.87 mm | 2.87 mm |
Cash burn (monthly) | (no burn) | 272.67 k | 1.33 mm | 1.89 mm | (no burn) | 942.33 k |
Cash used (since last report) | n/a | 1.88 mm | 9.20 mm | 13.06 mm | n/a | 6.50 mm |
Cash remaining | n/a | 991.32 k | -6.33 mm | -10.19 mm | n/a | -3.63 mm |
Runway (months of cash) | n/a | 3.6 | -4.7 | -5.4 | n/a | -3.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 4 |
Closed positions | 12 |
Increased positions | 2 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 435.62 mm |
Total shares | 9.92 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lind Global Fund II | 4.46 mm | $0.00 |
Intracoastal Capital | 2.73 mm | $0.00 |
ProQuest Investments III | 2.59 mm | $9.84 mm |
Armistice Capital | 122.00 k | $359.90 mm |
STT State Street | 10.84 k | $31.99 mm |
BLK Blackrock | 6.06 k | $17.88 mm |
Tower Research Capital | 2.71 k | $8.00 mm |
IVSBF Investor AB | 1.75 k | $5.17 mm |
RY Royal Bank Of Canada | 758.00 | $2.00 mm |
C Citigroup | 181.00 | $534.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Oct 23 | Coiante Scott M | Common Stock | Grant | Acquire A | No | No | 0 | 20,000 | 0.00 | 20,080 |
28 Jun 23 | Gilmore Geoffrey | Common Stock | Grant | Acquire A | No | No | 0 | 6,716 | 0.00 | 20,256 |
28 Jun 23 | Gilmore Geoffrey | Common Stock | Grant | Acquire A | No | No | 0 | 13,500 | 0.00 | 13,540 |
28 Jun 23 | Gilmore Geoffrey | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.48 | 4,500 | 11.16 k | 4,500 |
28 Jun 23 | Robert G Conway | Common Stock | Grant | Acquire A | No | No | 0 | 13,500 | 0.00 | 13,529 |
28 Jun 23 | Robert G Conway | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.48 | 4,500 | 11.16 k | 4,500 |
28 Jun 23 | Paul Korner | Common Stock | Grant | Acquire A | No | No | 0 | 13,500 | 0.00 | 13,500 |
28 Jun 23 | Paul Korner | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.48 | 4,500 | 11.16 k | 4,500 |
News
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
28 Mar 24
Agile Therapeutics: Q4 Earnings Insights
28 Mar 24
Agile Therapeutics's Earnings: A Preview
27 Mar 24
Why Agile Therapeutics (AGRX) Stock Is Down 60%
26 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
25 Mar 24
Press releases
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
25 Mar 24
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
21 Mar 24
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
20 Mar 24
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
13 Mar 24